Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pappa

Showing results (151-160 of 156) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 156 results.
Frontiers in Plant Science|December 6, 2016
A Comparative Nitrogen Balance and Productivity Analysis of Legume and Non-legume Supported Cropping Systems: The Potential Role of Biological Nitrogen FixationPietro P M Iannetta, Mark Young, Johann Bachinger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled AnalysisJoseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Annals of Internal Medicine|February 16, 2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1Eric S Daar, Camlin Tierney, Margaret A Fischl, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2020
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO StudyJean van Wyk, Faïza Ajana, Fiona Bisshop, et al.
AIDS (London, England)|September 17, 2021
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infectionPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2019
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical TrialsPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Pageof 16

Showing results (151-160 of 156) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 156 results.
Frontiers in Plant Science|December 6, 2016
A Comparative Nitrogen Balance and Productivity Analysis of Legume and Non-legume Supported Cropping Systems: The Potential Role of Biological Nitrogen FixationPietro P M Iannetta, Mark Young, Johann Bachinger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled AnalysisJoseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Annals of Internal Medicine|February 16, 2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1Eric S Daar, Camlin Tierney, Margaret A Fischl, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2020
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO StudyJean van Wyk, Faïza Ajana, Fiona Bisshop, et al.
AIDS (London, England)|September 17, 2021
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infectionPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2019
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical TrialsPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Pageof 16